Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients

MeSH terms

• Adult
• Brentuximab Vedotin / pharmacology
• Brentuximab Vedotin / therapeutic use
• Chemotherapy, Adjuvant / methods
• Drug Resistance, Neoplasm
• Female
• Hodgkin Disease / mortality
• Hodgkin Disease / pathology
• Hodgkin Disease / therapy*
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local / pathology
• Neoplasm Recurrence, Local / therapy*
• Nivolumab / pharmacology
• Nivolumab / therapeutic use*
• Progression-Free Survival
• Stem Cell Transplantation*
• Transplantation, Autologous
• Young Adult